Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules

Journal of Medicinal Chemistry

Volumn 50, Issue 14, 2007, Pages 3205-3213

  McMasters, Daniel R ^a   Torres, Rhonda A ^a,b   Crathern, Susan J ^a   Dooney, Deborah L ^a   Nachbar, Robert B ^a   Sheridan, Robert P ^a   Korzekwa, Kenneth R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; NITROGEN DERIVATIVE; RECOMBINANT ENZYME; SULFONAMIDE;

ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; DRUG SOLUBILITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; MICHAELIS CONSTANT;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; FLUORESCENCE; KINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECOMBINANT PROTEINS;

EID: 34447520297     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0700060     Document Type: Article

References (37)

1. Denisov, I. G.; Makris, T. M.; Sligar, S. G.; Schlichting, I. Structure and chemistry of cytochrome P450. Chem. Rev. 2005, 105, 2253-2277.
2. Makris, T. M.; Davydov, R.; Denisov, I. G.; Hoffman, B. M.; Sligar, S. G. Mechanistic enzymology of oxygen activation by the cytochromes P450. Drug Metab. Rev. 2002, 34, 691-708.
3. Atkins, W. M. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 291-310.
4. Kenworthy, K. E.; Clarke, S. E.; Andrews, J.; Houston, J. B. Multisite kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 2001, 29, 1644-1651.
5. Korzekwa, K. R.; Krishnamachary, N.; Shou, M.; Ogai, A.; Parise, R. A.; Rettie, A. E.; Gonzalez, F. J.; Tracy, T. S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998, 37, 4137-4147.
6. Shou, M.; Grogan, J.; Mancewicz, J. A.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V.; Korzekwa, K. R. Activation of Cyp3A4-Evidence for the simultaneous binding of two substrates in A cytochrome-P450 active-site. Biochemistry 1994, 33, 6450-6455.
7. Egnell, A. C.; Eriksson, C.; Albertson, N.; Houston, B.; Boyer, S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J. Pharmacol. Exp. Ther. 2003, 307, 878-887.
8. Hutzler, J. M.; Hauer, M. J.; Tracy, T. S. Dapsone activation of CYP2C9-mediated metabolism: Evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. 2001, 29, 1029-1034.
9. Hutzler, J. M.; Wienkers, L. C.; Wahlstrom, J. L.; Carlson, T. J.; Tracy, T. S. Activation of cytochrome P450 2C9-mediated metabolism: Mechanistic evidence in support of kinetic observations. Arch. Biochem. Biophys. 2003, 410, 16-24.
10. Afshar, M.; Thormann, W. Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450 SUPERSOMES: Evidence for atypical kinetics by CYP2D6 and CYP3A4. Electrophoresis 2006, 27, 1526-1536.
11. Kudo, S.; Odomi, M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur. J. Clin. Pharmacol. 1998, 54, 253-259.
12. Miller, G. P.; Guengerich, F. P. Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: Evidence for two binding sites. Biochemistry 2001, 40, 7262-7272.
13. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
14. Tracy, T. S.; Hummel, M. A. Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metab. Rev. 2004, 36, 231-242.
15. Hummel, M. A.; Tracy, T. S.; Hutzler, J. M.; Wahlstrom, J. L.; Zhou, Y.; and Rock, D. A. Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9. J. Biomol. Screening 2006, 11, 303-309.
16. Hurvich, C. M.; Tsai, C. L. Regression and time-series model selection in small samples. Biometrika 1989, 76, 297-307.
17. Egnell, A. C.; Houston, B.; Boyer, S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J. Pharmacol. Exp. Ther. 2003, 305, 1251-1262.
18. Liu, K. H.; Kim, M. J.; Jung, W. M.; Kang, W.; Cha, I. J.; Shin, J. G. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab. Dispos. 2005, 33, 209-213.
19. Ludwig, E.; Schmid, J.; Beschke, K.; Ebner, T. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J. Pharmacol. Exp. Ther. 1999, 290, 1-8.
20. Stresser, D. M.; Blanchard, A. P.; Turner, S. D.; Erve, J. C. L.; Dandeneau, A. A.; Miller, V. P.; Crespi, C. L. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metab. Dispos. 2000, 28, 1440-1448.
21. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 1999, 88, 807-814.
22. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
23. Margolis, J. M.; Obach, R. S. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab. Dispos. 2003, 31, 606-611.
24. Obach, R. S.; Walsky, R. L.; Venkatakrishnan, K.; Houston, J. B.; Tremaine, L. M. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: Qualitative relationships, quantitative predictions, and the rank-order approach. Clin. Pharmacol. Ther. 2005, 78, 582-592.
25. Tran, T. H.; von Moltke, L. L.; Venkatakrishnan, K.; Granda, B. W.; Gibbs, M. A.; Obach, R. S.; Harmatz, J. S.; Greenblatt, D. J. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab. Dispos. 2002, 30, 1441- 1445.
26. Venkatakrishnan, K.; von Moltke, L. L.; Obach, R. S.; Greenblatt, D. J. Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro. J. Pharmacol. Exp. Ther. 2000, 293, 343-350.
27. Shoichet, B. K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem. 2006, 49, 7274-7277.
28. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 2005, 1, 146-148.
29. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 2003, 46, 4477-4486.
30. Galetin, A.; Clarke, S. E.; Houston, J. B. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: Midazolam, testosterone, and nifedipine. Drug Metab. Dispos. 2003, 31, 1108-1116.
31. Houston, J. B.; Galetin, A. Modelling atypical CYP3A4 kinetics: Principles and pragmatism. Arch. Biochem. Biophys. 2005, 433, 351-360.
32. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem. 2006, 281, 7614-7622.
33. Ekroos, M.; Sjogren, T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13682-13687.
34. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature 2003, 424, 464-468.
35. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0-angstrom resolution. J. Biol. Chem. 2004, 279, 35630-35637.
36. Strobl, G. R.; von Kruedener, S.; Stockigt, J.; Guengerich, F. P.; Wolff, T. Development of a pharmacophore for inhibition of human liver cytochrome-P-450 2D6 - Molecular modeling and inhibition studies. J. Med. Chem. 1993, 36, 1136-1145.
37. Dickmann, L. J.; Locuson, C. W.; Jones, J. P.; Rettie, A. E. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol. Pharmacol. 2004, 65, 842-850.